Our model simplifies the heterogeneity of the tumor microenvironment by focusing on one of the major cellular targets of AAT, but incorporates several key factors such as functional VEGFA blockade by bevacizumab and the specialized serum-free medium for optimizing EC survival under VEGFA-dependent culture conditions. Here, SERPINA1 is linked to neoplasm.